Angelalign Reports Strong 2025 Financial Results: Open Corporate Culture Drives Talent Integration and Sustained Growth in China and Global Markets

On March 27, 2026, ANGELAIGN (6699.HK) released its annual results for 2025. During the reporting period, the company maintained strong business performance, achieving a total of 532,400 cases for the full year, a year-on-year increase of 48.1%, and generating revenue of USD 370.3 million, up 37.8% year on year. Driven by its medical mission, the company leveraged the advantages of its open corporate culture, harnessed global talent, and built an efficient organizational structure to meet the clinical needs of customers worldwide.

Hu Jiezhang, CEO of ANGELAIGN, stated, “The clear aligner orthodontics industry is characterized by highly complex and diverse technologies, requiring top-tier technical and operational talent, as well as efficient collaboration among professionals from different countries to contribute their experience and expertise. Therefore, ANGELAIGN’s distinctive open corporate culture demonstrates significant advantages. We attract and unite professionals and managers with diverse cultural backgrounds from around the world, focusing on shared medical objectives to deliver exceptional products and services. It is this inclusive corporate culture that drives ANGELAIGN’s long-term development.”

Clear aligner orthodontics is characterized by long treatment cycles, wherein differences in product quality and treatment planning accumulate and gradually become apparent over the course of therapy, which may involve up to hundreds of aligners. Consequently, distinguished orthodontists typically require years of hands-on clinical validation before fully endorsing and adopting a particular brand. Meanwhile, as one of the most advanced specialties, orthodontics has fostered tight-knit professional communities worldwide. Leading orthodontic experts continuously share their clinical experiences and build consensus throughout the treatment process, thereby influencing the adoption patterns of the broader practitioner community.

In light of these two characteristics of the global orthodontics industry, ANGELAIGN has chosen a challenging development path that diverges from conventional export trade—by directly entering top-tier cities worldwide to serve leading orthodontists with high-quality localized services and clinical support. With the joint support of global investors and employees, ANGELAIGN has invested substantial resources and undergone complex organizational restructuring to meet the demand for highly professional services among orthodontists worldwide.

After three years of consolidation, ANGELAIGN has achieved tangible progress in the global market. Today, in numerous major first-tier cities including New York, London, Paris, Tokyo, Madrid, Sydney, Los Angeles, Boston, Cologne, and São Paulo, ANGELAIGN has established a strong reputation among industry key opinion leaders (KOLs), earning particular favor from clinicians who pursue excellence in clinical value. Hundreds of international orthodontic experts have each treated at least 100 cases using ANGELAIGN products, with some managing over 1,000 cases, particularly complex ones. This professional credibility, built on firsthand experience, is radiating outward and gradually influencing mainstream practitioner communities across various countries. Meanwhile, the global medical community has gained a deeper understanding of the differences in clinical outcomes and predictability among clear aligner products, further solidifying the competitive advantage of leading international brands such as ANGELAIGN.

In addition to its mature products and medical services, the innovative wave brought by ANGELAIGN has also been warmly received by doctors worldwide. Taking the Angel Button solution as an example, this product has been on the market for six years, with over 100 million clinical applications globally. Extensive user feedback has provided a crucial basis for further enhancing the product’s industrial stability and clinical predictability. Today, the Angel Button solution is widely recognized; its stable and mature traction efficacy, along with numerous supporting biomechanical movement designs, have effectively improved treatment efficiency and patient comfort. Another innovation case is the ANGELAIGN A6 Mandibular Advancement Solution, which has achieved excellent clinical outcomes through ten years of clinical application feedback and continuous iteration. ANGELAIGN’s innovations focus on addressing clinicians’ pain points and optimizing patient experience, rather than chasing the latest technological trends. More importantly, even the most brilliant innovative thinking requires long-term clinical use and continuous refinement to achieve predictable treatment outcomes.

ANGELAIGN collaborates closely with orthodontists from diverse backgrounds worldwide, integrating their innovative insights into the development and validation of next-generation solutions. Its open corporate culture plays a pivotal role in this process, enabling ANGELAIGN to incorporate feedback from internal employees and suggestions from global orthodontists. Leveraging this culture, ANGELAIGN further capitalizes on its organizational structure by efficiently integrating R&D, medical, commercial, and operational teams to deliver localized solutions that meet the unique requirements of more than 60 countries.

Currently, the Company has established highly specialized teams for medical education and training, clinical support, and sales across five regional markets: Europe, the Middle East and Africa (EMEA), North America, Asia-Pacific, South America, and China. To address the evolving international landscape, the Company has set up medical design centers in China, Brazil, and Southeast Asia, and established aligner manufacturing centers in China, the United States, and Brazil. Meanwhile, as innovative achievements continue to accumulate, the Company will steadily increase its compliance investments, strengthen its data security framework, build robust intellectual property barriers, and take necessary measures to safeguard its innovative outcomes.

In 2025, ANGELAIGN’s global market (excluding mainland China) recorded 256,200 cases, representing a year-on-year increase of 82.1%, with revenue reaching USD 163.0 million, a year-on-year growth of 102.5%. As the number of high-quality cases continues to grow, an increasing number of distinguished orthodontic specialists are proactively recommending ANGELAIGN to their peers, particularly for complex cases, and publishing papers in professional journals, thereby propelling the company’s global business into a new phase of growth driven by professional reputation.

China's clear aligner orthodontics market exhibits a distinct multi-tiered structure, with significant regional disparities in clinician expertise, patient demand, and healthcare service delivery models.

In China’s first- and second-tier cities, ANGELAIGN continues to leverage its mature medical service system and stable operational support capabilities to collaborate closely with clinicians, establishing high-level clinical benchmarks. In 2025, the company integrated traditional orthodontic principles with digital innovation tools, launching new technologies such as the Angel Surface Guide and Angel Occlusion Guide for complex adult cases, thereby providing stronger support for clinicians in the diagnosis and treatment of challenging cases. For pediatric and adolescent patients, the company introduced a series of products tailored to the characteristics of growth and development, making treatment simpler and more comfortable for younger patients. The iOrtho orthodontic design platform for clinicians undergoes biweekly version iterations and, combined with product innovations, delivers a smoother clinical and workflow experience.

In China’s vast tier-3 and tier-4 cities, ANGELAIGN is firmly committed to serving the lower-tier markets. Through systematic physician training, clinical support, and full-cycle solutions, we help more doctors consistently deliver clear aligner therapy, significantly enhancing the predictability of treatment outcomes, shortening treatment duration, and reducing case restart rates, thereby enabling a broader patient population to access high-standard care.

As some clear aligner brands withdraw from the market in third- and fourth-tier cities, ANGELAIGN’s leading position and influence in these lower-tier markets have further expanded. The underlying reason for this shift is that dentists in third- and fourth-tier cities are increasingly recognizing that disparities among brands in manufacturing processes, medical design, and clinical support capabilities become progressively more pronounced during treatment. This often results in difficulties completing certain cases smoothly, while the need for manufacturers to continue shipping aligners leads to a surge in potential costs. Based on this assessment, a large number of dentists in third- and fourth-tier cities are proactively choosing top-tier brands that better ensure treatment outcomes. Notably, some clear aligner brands that have ceased operations have also actively advised their partner dentists, with patient consent, to transfer cases to leading brands, and are cooperating fully to help dentists successfully complete subsequent patient treatments.

In 2025, ANGELAIGN’s case volume in the Chinese mainland market reached 276,200, a year-on-year increase of 26.3%, with revenue amounting to USD 207.3 million, up 10.1% year on year. Among physicians in lower-tier markets, ANGELAIGN has established leading market share and brand influence, while continuously expanding its market coverage. For ANGELAIGN, its firm commitment to the Chinese lower-tier markets signifies not only an expansion of business reach, but also the provision of stable product and service support to more physicians in these regions, thereby enabling more patients to benefit from standardized clear aligner orthodontic treatment.

To date, ANGELAIGN’s cumulative total case count has surpassed 2 million. This marks a significant milestone—ANGELAIGN’s cases have historically been predominantly complex, whereas simple cases represent a distinct category with different technological barriers. The significance of these 2 million cases lies in the fact that each one reflects the outcome of intricate collaboration among numerous talented professionals driven by a medical mission. This deep integration of culture, team, systems, and total case volume constitutes the solid foundation for ANGELAIGN’s long-term development.

Looking ahead, the global clear aligner industry still holds vast potential for growth. ANGELAIGN will uphold its open corporate culture, remain committed to increasing investment in technological innovation, continuously strengthen its global clinical service system, and further enhance customer experience across all countries. The company is confident that these efforts will effectively drive sustainable growth in its businesses across various regions worldwide.

Founded in 2003, ANGELAIGN is a publicly listed company widely recognized by international capital, having delivered over 2 million smiles to date. The company provides digital technology-driven clear aligner products and services to more than 60 countries.